Cloudbreak Pharma-B (02592) Sets 30 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend

Bulletin Express
03/18

Cloudbreak Pharma Inc. (Stock Code: 02592) has scheduled a board meeting for Monday, 30 March 2026. Key agenda items include:

• Approval of the Group’s audited annual results for the financial year ended 31 December 2025. • Deliberation on the recommendation of a final dividend, if any, for the period under review.

The meeting will be chaired by Dr. Ni Jinsong, who serves as Chairman, Executive Director and Chief Executive Officer. The current Board structure comprises:

• Executive Directors: Dr. Ni Jinsong, Mr. Dinh Son Van, Dr. Yang Rong. • Non-Executive Directors: Dr. Li Jun Zhi, Mr. Cao Xu, Mr. Xia Zhidong. • Independent Non-Executive Directors: Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter, Mr. Lee Alex Jao Jang.

The announcement was released in Hong Kong on 18 March 2026.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10